- Home
- WBX vs DSGN Comparison
WBX vs DSGN Comparison
Compare WBX & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WBX
- DSGN
- Stock Information
- Founded
- WBX 2015
- DSGN 2017
- Country
- WBX Spain
- DSGN United States
- Employees
- WBX N/A
- DSGN N/A
- Industry
- WBX Industrial Specialties
- DSGN Biotechnology: Pharmaceutical Preparations
- Sector
- WBX Consumer Discretionary
- DSGN Health Care
- Exchange
- WBX Nasdaq
- DSGN Nasdaq
- Market Cap
- WBX 293.9M
- DSGN 348.2M
- IPO Year
- WBX N/A
- DSGN 2021
- Fundamental
- Price
- WBX $0.65
- DSGN $6.17
- Analyst Decision
- WBX Buy
- DSGN Hold
- Analyst Count
- WBX 3
- DSGN 3
- Target Price
- WBX $1.42
- DSGN $7.00
- AVG Volume (30 Days)
- WBX 1.2M
- DSGN 206.4K
- Earning Date
- WBX 02-26-2025
- DSGN 11-07-2024
- Dividend Yield
- WBX N/A
- DSGN N/A
- EPS Growth
- WBX N/A
- DSGN N/A
- EPS
- WBX N/A
- DSGN N/A
- Revenue
- WBX $179,622,844.00
- DSGN N/A
- Revenue This Year
- WBX $20.24
- DSGN N/A
- Revenue Next Year
- WBX $16.77
- DSGN N/A
- P/E Ratio
- WBX N/A
- DSGN N/A
- Revenue Growth
- WBX 16.10
- DSGN N/A
- 52 Week Low
- WBX $0.41
- DSGN $2.25
- 52 Week High
- WBX $1.87
- DSGN $7.77
- Technical
- Relative Strength Index (RSI)
- WBX 57.40
- DSGN 50.45
- Support Level
- WBX $0.42
- DSGN $6.04
- Resistance Level
- WBX $0.58
- DSGN $6.53
- Average True Range (ATR)
- WBX 0.07
- DSGN 0.49
- MACD
- WBX 0.02
- DSGN -0.03
- Stochastic Oscillator
- WBX 82.80
- DSGN 53.72
About WBX Wallbox N.V.
Wallbox NV is a smart electric vehicle charging and energy management company. It creates smart charging system combining technology design that manages the communication between user, vehicle, grid, building, and charger. The company is engaged in designing, manufacturing, and distributing faster, simpler EV charging solutions for residential, business, and public use. Its smart charging product portfolio includes Level 2 alternating current chargers for home and business applications and direct current fast chargers for public applications. The company has three reportable operating segments; Europe, Middle East and Asia (EMEA) which is also its key revenue generating segment, North America, and Asia‑Pacific.
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.